Precision Optics Corporation, Inc. (POCI) Stock

Precision Optics Corporation, Inc. (POCI) is a Healthcare stock trading at $4.46 (as of 2026-08-20), with a market capitalization of $48.76M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components, including medical instrumentation such as endoscopes and endocouplers, custom imaging and illumination products, and 3D endoscopic equipment. It also supplies components and assemblies for industrial and military uses, with products marketed to medical device companies.

Understand Precision Optics Corporation, Inc.: how it makes money

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems, including medical instrumentation like endoscopes and imaging components, and also provides components and assemblies for industrial and military use. It makes money by selling these engineered products and related components.

The profit engine appears to be production revenue from complex, engineered optics and illumination systems, where manufacturing yields (for example, Single-Use Cystoscope Daily Yield and Aerospace Program Production Yield) help determine how much usable output can be converted into sellable products and delivered revenue.

Revenue by segment (latest quarter)
Production$0.0B
DevelopmentEng$0.0B

Business quality (Weak): In the latest provided quarter, operating profitability was negative (operating margin -0.7) despite positive gross margin (23.6), and most segment revenue is shown as near zero, so the near term path from development progress into sustained production revenue is the key watch item in this dataset.

Bull case

  • Operational progress shows measurable execution in product development work: Design Validation Units Completed for Single-Use Ophthalmology Program is listed as 500 (count).
  • Manufacturing performance indicators are provided and are not at extreme levels: Single-Use Cystoscope Daily Yield is listed as 50 percent, and Aerospace Program Production Yield is listed as 97 percent.

Bear case

  • Near term operating profitability is weak: Operating margin is -0.7 for the quarter ended 2026-03-31.
  • Revenue scale appears very small in the provided quarter: Total revenue is shown as 0.0B, while only Production Revenue is listed as 0.01B and other revenue categories are shown as 0.0B.
Valuation — source: SEC EDGAR (first-party)
Price$4.46
Market Cap$48.76M
Price / Book2.43
Price / Sales1.81
FCF Yield-6.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$19.09M
Net Margin-30.3%
Revenue Growth (YoY)108.0%
EPS Growth (YoY)-96.7%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.02 (distress)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderNEEDHAM INVESTMENT MANAGEMENT LLC ($7.33M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOJoseph N. Forkey
Employees83
CountryUS
IPO Date1992-01-16

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • FONAR Corporation (FONR)
  • Vivani Medical, Inc. (VANI)
  • Streamex Corp. (STEX)
  • electroCore, Inc. (ECOR)
  • Hyperfine, Inc. (HYPR)
  • Outset Medical, Inc. (OM)
  • NeurAxis, Inc. (NRXS)
  • QT Imaging Holdings, Inc. (QTI)
POCI earnings history · POCI institutional & insider holders · POCI KPIs & operating metrics · POCI financials · POCI investor presentations & press releases · POCI SEC filings · POCI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.